- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | Caspase-3/7 Inhibitor Z-DEVD-FMK (20 mM) |
| Catalog No. | RESK-0509 |
| Description | Z-DEVD-FMK is a cell-permeable, irreversible caspase-3 inhibitor (IC50 = 130 nM) that also effectively inhibits caspase-6, caspase-7, caspase-8 and caspase-10, thereby efficiently suppressing tumor cell apoptosis. Z-DEVD-FMK significantly reduces maitotoxin-induced neuronal cell death and markedly decreases the expression of the 145 KD calpain-mediated alpha-spectrin product. In addition, early treatment with Z-DEVD-FMK improves neurological function and reduces lesion volume. This product is a stock solution in DMSO at a concentration of 20 mM. In vitro (literature data): when glial cells are co-treated with maitotoxin and Z-DEVD-FMK (1 nM - 10 uM), Z-DEVD-FMK shows a neuroprotective effect, reduces LDH release and attenuates neuronal cell death. In vivo (literature data): mice subjected to CCI were injected intracerebroventricularly with 160 ng Z-DEVD-FMK at 1, 4, 8 or 24 h after CCI; Z-DEVD-FMK administered 1 h after CCI significantly reduced the lesion volume and improved neurological function. |
| Intended Use | For apoptosis research: inhibition of caspase-3/7 and related executioner caspases in cell-based and animal studies. |
| Principle / Technology | Cell-permeable, irreversible peptide fluoromethyl ketone (FMK) caspase inhibitor targeting caspase-3 (IC50 = 130 nM), with activity against caspase-6, -7, -8 and -10. |
| Sample Type | Cultured cells (e.g., glial cells); animal models (mouse) in literature-reported studies. |
| Performance Range / Specifications | Chemical Name: N-[(phenylmethoxy)carbonyl]-L-alpha-aspartyl-L-alpha-glutamyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-L-valinamide, 1,2-dimethyl ester Target: Caspase-3 CAS No.: 210344-95-9 Molecular Formula: C30H41FN4O12 Molecular Weight: 668.66 Appearance: Liquid Purity: ≥95% |
| Sensitivity / LOD | Inhibits caspase-3 with an IC50 of 130 nM. |
| Specificity | Irreversible caspase-3 inhibitor; also inhibits caspase-6, caspase-7, caspase-8 and caspase-10. |
| Reaction Conditions / Protocol | The optimal working concentration should be determined by referring to relevant literature and optimized according to your experimental conditions (e.g., experimental purpose, cell type and culture characteristics). In vitro (literature data): co-treatment of glial cells with maitotoxin and Z-DEVD-FMK (1 nM - 10 uM) reduces LDH release and attenuates neuronal cell death. In vivo (literature data): intracerebroventricular injection of 160 ng Z-DEVD-FMK at 1, 4, 8 or 24 h after CCI in mice; administration 1 h after CCI significantly reduces lesion volume and improves neurological function. |
| Components / Formulation | Stock solution of Z-DEVD-FMK in DMSO, 20 mM. |
| Storage Conditions | Store at -25 to -15 °C; avoid repeated freeze-thaw cycles. |
| Shelf Life | At least 6 months when stored at -25 to -15 °C. |
| Package Specifications | 20 uL |
| Product Form | Liquid (DMSO stock solution) |
| Purity | ≥95% |
| Concentration | 20 mM |
| Molecular Weight | 668.66 |
| Regulatory / Compliance | For research use only. |
| Application Notes / Precautions | Avoid repeated freeze-thaw cycles. The optimal working concentration varies with experimental conditions and should be optimized empirically. |
For research use only, not for clinical use.
|
There is no product in your cart. |